AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01051973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: A 10-week treatment based on exposure to symptoms and related feelings.
Study NCT01051973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management
Description: A 10-week stress management treatment including applied relaxation and dietary advice.
Study NCT05467865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZELIAKIDE
Description: The nutrition education program will be adapted to the curriculum of the schools. The intervention will consist of 8 sessions and the main topics will be: (1) to understand the balanced diet and to apply it to one´s own diet, (2) to learn what celiac disease and gluten are, (3) to promote social inclusion.~Each session will last 60 minutes and they will take place during school hours. The whole intervention will last 4 weeks, 2 sessions per week. Teaching-learning process will be developed through games and experiments.~Designed activities are based on IBL methodology, which has proven to be very effective in science teaching-learning processes. As a result, inquiry-oriented TLS has been developed, focused on facilitating children's understanding of the research process.
Study NCT00669136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Description: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Study NCT00245427 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: all macrolide antibiotics
Description: Varies based on antibiotic
Study NCT00245427 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: all beta-lactam antibiotics
Description: Varies based on antibiotic
Study NCT01629134 — intervention group
Intervention type: DEVICE
Intervention: Crosslinked hyaluronic acid gel
Description: All treatments are carried out according to the physician's experience and the Directions for Use
Study NCT01227096 — intervention group
Intervention type: DEVICE
Intervention: Electrical acupuncture stimulation
Description: electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
Study NCT03606239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: isotoxic hypofractionated group
Description: the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
Study NCT02913469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The patients in group A would be administrated intravenous morphine 5mg
Study NCT02913469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: The patients in group A would be administrated intravenous morphine 5mg
Study NCT02913469 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: metoclopramide
Description: the patients in group C would be administrated intravenous metoclopramide 10mg
Study NCT02913469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: the patients in group C would be administrated intravenous metoclopramide 10mg
Study NCT02913469 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline
Description: the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
Study NCT02913469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
Study NCT02913469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
Study NCT00393978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine and placebo
Description: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
Study NCT01702623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Study NCT01524159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bromelain capsule
Description: Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
Study NCT01524159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (wheat starch)
Description: Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
Study NCT00393978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine and Topiramate
Description: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
Study NCT00637052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Study NCT02173691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation powder capsules
Study NCT02173691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol inhalation aerosol
Study NCT02173691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation aerosol
Study NCT02173691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation aerosol
Study NCT02173691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder capsules
Study NCT02173691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhalation powder capsules
Study NCT01894386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF 400 mcg
Description: 100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
Study NCT01573494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling of blood
Description: 7,5 ml of blood
Study NCT01894386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 500 mcg
Description: 125 mcg powder for inhalation delivered by DPI
Study NCT01894386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 250 mcg
Description: 62.5 mcg powder for inhalation delivered by DPI
Study NCT01894386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI 100 mcg
Description: 25 mcg powder for inhalation delivered by DPI
Study NCT03631680 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral Oophorectomy Surgery
Description: Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
Study NCT02837731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Starling SV monitor
Description: A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
Study NCT03351608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
Study NCT03351608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
Study NCT03351608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine + Glycopyrrolate
Description: For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
Study NCT03351608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine + Atropine
Description: For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
Study NCT03778346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T therapy in Relapsed/Refractory multiple myeloma
Description: Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma
Study NCT01017536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
Study NCT01017536 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was the identical buffer solution in which AERAS-402 is formulated.
Study NCT01186068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V-101
Description: Cream QD
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Placebo capsules
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive marijuana (0% THC)
Description: Inactive marijuana cigarettes (0% THC) provided by NIDA
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive marijuana (0% THC)
Description: Inactive marijuana cigarettes (0% THC) provided by NIDA
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Dronabinol
Description: Dronabinol 10mg
Study NCT01186068 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: Cream QD
Study NCT01730989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Estromineral Serena Plus
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Dronabinol
Description: Dronabinol 20mg
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low THC marijuana
Description: marijuana cigarettes (1.98% THC) provided by NIDA
Study NCT00743119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC marijuana
Description: Marijuana cigarettes (3.56% THC) provided by NIDA
Study NCT02825472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: 3 times per week 30 minutes of exercise training in the target heart rate zone
Study NCT02516878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated.
Study NCT02516878 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated.
Study NCT02488707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic intersphincteric resection (LISR group)
Description: the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
Study NCT02488707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal minimally invasive Total mesorectal excision (TAMIS group)
Description: Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
Study NCT04556838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN001 Ophthalmic Solution 1%
Description: VVN001 Ophthalmic Solution 1%
Study NCT04556838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN001 Ophthalmic Solution 5%
Description: VVN001 Ophthalmic Solution 5%
Study NCT04556838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: VVN001 Ophthalmic Solution Vehicle
Study NCT03853213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification Training
Description: In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given.
Study NCT03853213 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control Training
Description: In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
Study NCT00995930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: ACZ885 150 mg was administered subcutaneously once a month for 12 months.
Study NCT00995930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
Study NCT03516838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTIVA™ BioACTIVE
Description: Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
Study NCT03516838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compomer
Description: Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
Study NCT04380701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162a1
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT04380701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT04380701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT04380701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162c2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT00763269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan, Silicon dioxide, fluoride
Description: Brush twice daily
Study NCT00763269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Brush twice daily
Study NCT02999919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: 12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
Study NCT01367262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Administered orally
Study NCT01146431 — intervention group
Intervention type: DRUG
Intervention: Inhaled anesthetics
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
Study NCT01146431 — intervention group
Intervention type: DRUG
Intervention: Inhaled anesthetics
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
Study NCT04266119 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online HOPE intervention
Description: Online HOPE intervention to increase mental health literacy
Study NCT04266119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online HOPE intervention
Description: Online HOPE intervention to increase mental health literacy
Study NCT03432026 — intervention group
Intervention type: DEVICE
Intervention: High resolution computed tomography scan of the chest.
Description: High resolution computed tomography scan of the chest \& pulmonary function tests will be done for every patient to classify them.
Study NCT02869828 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Monitoring by arterial catheter and Spot-on
Study NCT02869828 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Monitoring by oesophagal probe and Spot-on
Study NCT04007588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
Study NCT04007588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
Study NCT04007588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
Study NCT01468168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 Ophthalmic Suspension
Description: Ophthalmic suspension; QID
Study NCT01468168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-101 Ophthalmic Suspension Vehicle
Description: Ophthalmic suspension vehicle; QID
Study NCT01128153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg tablet once daily for 24 weeks to be taken orally
Study NCT01128153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet once daily for 24 weeks to be taken orally
Study NCT00148694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously once every three weeks for a total of 12 weeks